Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
2007

Impact of Nesiritide on Heart Failure Outcomes

Sample size: 25330 publication 10 minutes Evidence: moderate

Author Information

Author(s): Carroll Richard J, Mulla Zuber D, Hauck Loran D, Westbrook Audrey

Primary Institution: Adventist Health System

Hypothesis

Does nesiritide treatment affect outcomes in patients hospitalized for acute decompensated heart failure?

Conclusion

Nesiritide therapy was associated with increased length of stay and pharmacy cost, but not hospital mortality.

Supporting Evidence

  • Nesiritide was associated with a 59% higher odds of hospital mortality initially.
  • After adjustments, the odds ratio for hospital mortality became nonsignificant.
  • Nesiritide treatment was linked to a prolonged length of stay and elevated pharmacy costs.

Takeaway

This study looked at patients with heart failure and found that using a drug called nesiritide made them stay in the hospital longer and cost more money, but it didn't seem to help them live longer.

Methodology

Retrospective analysis of CHF patients discharged from a hospital system over three years, comparing outcomes based on nesiritide treatment.

Potential Biases

Sicker patients may have been more likely to receive nesiritide, introducing bias.

Limitations

The study design is observational and cannot account for unmeasured confounding factors.

Participant Demographics

Patients were primarily adults aged 18 and older, with a median age of 74 years for those receiving nesiritide.

Statistical Information

P-Value

0.03

Confidence Interval

95% CI: 1.31–1.93

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2261-7-37

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication